Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)

Chandra Belani, G. Goss, G. Blumenschein

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

While chemotherapy has been the standard of care for patients with advanced non-small cell lung cancer (NSCLC), efforts have shifted toward evaluating novel targeted agents in an attempt to improve outcome. These targeted agents are directed toward key components in several signalling pathways such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 receptor (IGF-IR). There is also increasing interest in using combinations of targeted agents to inhibit more than one pathway; for example, inhibition of VEGFR. +. EGFR and VEGFR. +. PDGFR. +. EGFR. Further investigation is needed to identify the most appropriate combinations of these targeted agents in select patient subgroups, and to define optimal treatment doses to thereby achieve the best therapeutic index. This review outlines the rationale for combining targeted agents for the treatment of advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)173-184
Number of pages12
JournalCancer Treatment Reviews
Volume38
Issue number3
DOIs
StatePublished - May 1 2012

Fingerprint

Vascular Endothelial Growth Factor Receptor
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Platelet-Derived Growth Factor Receptors
Somatomedin Receptors
Standard of Care
Insulin-Like Growth Factor I
Therapeutics
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{808f3afcc9c44718801994fc7413ab19,
title = "Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)",
abstract = "While chemotherapy has been the standard of care for patients with advanced non-small cell lung cancer (NSCLC), efforts have shifted toward evaluating novel targeted agents in an attempt to improve outcome. These targeted agents are directed toward key components in several signalling pathways such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 receptor (IGF-IR). There is also increasing interest in using combinations of targeted agents to inhibit more than one pathway; for example, inhibition of VEGFR. +. EGFR and VEGFR. +. PDGFR. +. EGFR. Further investigation is needed to identify the most appropriate combinations of these targeted agents in select patient subgroups, and to define optimal treatment doses to thereby achieve the best therapeutic index. This review outlines the rationale for combining targeted agents for the treatment of advanced NSCLC.",
author = "Chandra Belani and G. Goss and G. Blumenschein",
year = "2012",
month = "5",
day = "1",
doi = "10.1016/j.ctrv.2011.05.009",
language = "English (US)",
volume = "38",
pages = "173--184",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "3",

}

Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). / Belani, Chandra; Goss, G.; Blumenschein, G.

In: Cancer Treatment Reviews, Vol. 38, No. 3, 01.05.2012, p. 173-184.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)

AU - Belani, Chandra

AU - Goss, G.

AU - Blumenschein, G.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - While chemotherapy has been the standard of care for patients with advanced non-small cell lung cancer (NSCLC), efforts have shifted toward evaluating novel targeted agents in an attempt to improve outcome. These targeted agents are directed toward key components in several signalling pathways such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 receptor (IGF-IR). There is also increasing interest in using combinations of targeted agents to inhibit more than one pathway; for example, inhibition of VEGFR. +. EGFR and VEGFR. +. PDGFR. +. EGFR. Further investigation is needed to identify the most appropriate combinations of these targeted agents in select patient subgroups, and to define optimal treatment doses to thereby achieve the best therapeutic index. This review outlines the rationale for combining targeted agents for the treatment of advanced NSCLC.

AB - While chemotherapy has been the standard of care for patients with advanced non-small cell lung cancer (NSCLC), efforts have shifted toward evaluating novel targeted agents in an attempt to improve outcome. These targeted agents are directed toward key components in several signalling pathways such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR) and insulin-like growth factor 1 receptor (IGF-IR). There is also increasing interest in using combinations of targeted agents to inhibit more than one pathway; for example, inhibition of VEGFR. +. EGFR and VEGFR. +. PDGFR. +. EGFR. Further investigation is needed to identify the most appropriate combinations of these targeted agents in select patient subgroups, and to define optimal treatment doses to thereby achieve the best therapeutic index. This review outlines the rationale for combining targeted agents for the treatment of advanced NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=84857658325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857658325&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2011.05.009

DO - 10.1016/j.ctrv.2011.05.009

M3 - Review article

C2 - 21715100

AN - SCOPUS:84857658325

VL - 38

SP - 173

EP - 184

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 3

ER -